Xconomy National

Archives

by in

Entry	Author	Date	Location
Angry at the Genome	Emily Walsh	01/25/12	Boston
Allozyne “Redistributes” Workforce After Scrapping Poniard Merger Plan	Luke Timmerman	01/03/12	Seattle
Allozyne Raises More VC Cash, Looks to FDA Meeting After Poniard Deal Fizzles	Luke Timmerman	12/23/11	Seattle
Aileron Expands Roche Deal, Agios Gets $78M, Genzyme MS Drug Advances, & More Boston-Area Life Sciences News	Erin Kutz	11/18/11	Boston
Genzyme MS Drug Significantly Reduces Relapse, Disability in Late-Stage Trial	Arlene Weintraub	11/14/11	Boston
Today’s Xconomy Report: Biogen Idec Meets Goals in Clinical Trial, iRobot Layoffs, $1M Awarded by MassChallenge, and Bay State Venture Capital Earnings	Lilly O'Flaherty	10/28/11	Boston
New Genzyme CEO, Biogen Scores in 2nd MS Pill Trial, Nanotech Drug Startups Nab Funds, & More Boston-Area Life Sciences News	Erin Kutz	10/28/11	Boston
Biogen Idec’s Oral Multiple Sclerosis Drug Passes 2nd Major Test; Stock Soars	Luke Timmerman	10/26/11	Boston
Sha Mi, Biogen Idec’s Neurology Ace, to Join “The Genetics Institute Impact” on Dec. 14	Luke Timmerman	10/21/11	Boston
Allozyne Looks to Rustle Up Interest on Wall Street With Backdoor IPO	Luke Timmerman	07/13/11	Seattle
Coronado Biosciences Pulls in $25.8 Million	Arlene Weintraub	07/06/11	New York
Allozyne Acquires Poniard Pharmaceuticals, Finds Backdoor Route to NASDAQ	Luke Timmerman	06/22/11	Seattle
Biogen Idec CEO on Move Back to Cambridge: “We’re Working on It”	Luke Timmerman	06/16/11	Boston
Proteostasis Nabs Partnership, $20M Investment, from Elan To Pursue Neurology Drugs	Luke Timmerman	05/25/11	Boston
Biogen Gets EU Panel OK for MS Drug	Luke Timmerman	05/20/11	Boston
Alkermes Acquires Elan Drug Manufacturing Unit for $960M	Luke Timmerman	05/09/11	Boston
Immune Design, Developer of New Vaccines, Adds Former Elan President as New CEO	Luke Timmerman	04/27/11	Seattle
Biogen Shares Jump on Good News on Revenue, Oral MS Drug	Ryan McBride	04/21/11	Boston
BG Medicine Chief Speaks on Rough IPO Climate, (Finally) Going Public	Ryan McBride	04/21/11	Boston
Acorda Issued Patent on MS Drug Following Days of Speculation	Arlene Weintraub	04/19/11	New York
Aveo Adds Termeer to Board, Monsanto Partners With Atlas, Biogen Drug Meets Clinical Goal, & More Boston-Area Life Sciences News	Erin Kutz	04/15/11	Boston
Acorda Stock Halted as Shares Skyrocket on Patent Speculation	Arlene Weintraub	04/14/11	New York
Biogen Idec Passes Pivotal Trial With Oral MS Drug; Shares Climb	Luke Timmerman	04/11/11	Boston
Experience Project Launches BroadCause, Putting Social Media to Work for Charitable Causes—and the Corporations Backing Them	Wade Roush	04/05/11	San Francisco
Genzyme-Spinout Peptimmune Files for Chapter 7 Liquidation	Ryan McBride	03/23/11	Boston
RXi Sells Stock and Warrants, Cardiorobotics Raises $6.6M, ImmunoGen Dishes On New Drugs, & More Boston-Area Life Sciences News	Erin Kutz	03/04/11	Boston
FDA Wants More Data on Merck KGaA’s MS Pill As Biogen Develops Rival Therapy	Ryan McBride	03/02/11	Boston
Genzyme, After Months of Holding Out, Agrees to be Sold to Sanofi-Aventis for $20.1B	Ryan McBride	02/16/11	Boston
Biogen Board OK’s 20M Share Buyback	Ryan McBride	02/14/11	Boston
Genzyme-Sanofi Deal Might Be Close, Report Says	Ryan McBride	02/01/11	Boston
Page 1 of 5	next page »